Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2025 16:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on...
September 17, 2025 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for...
September 11, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program...
September 08, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on...
September 04, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of...
September 03, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact...
September 02, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled...
August 27, 2025 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma...
August 06, 2025 07:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025...
July 31, 2025 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications staff has determined that the closing bid...